11119 North Torrey Pines Road
+1 858 550 7500
Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue.
Ligand has assembled one of the largest and most diverse portfolios in the biotech and pharmaceutical industry. Our partners and licensees fund the development and commercialization of our portfolio and we are entitled to receive royalties and milestones on program success. Currently approved portfolio drugs include those that treat cancer, osteoporosis, fungal infections and low blood platelets, among others. Our partners and licensees have programs currently in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney disease, among others.
Through a combination of research and acquisitions, Ligand has created a partnered portfolio with a wide variety of underlying technologies. This diversification provides the added benefits of exposure to a wider variety of science, more licensing opportunities and lower impact of individual patent expiry.
We are pleased Verona Pharma $VRNA and Nuance Pharma have formed a $219M strategic collaboration to develop and commercialize #ensifentrine in Greater China. Verona will receive $40M upfront and up to $179M in potential milestone payments plus royalties. https://t.co/EV3ZOX9NUD pic.twitter.com/2WqZScNkOM— Verona Pharma (@VeronaPharma) June 10, 2021